Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antireflux Activity of Z0063 vs Gaviscon in Healthy Adults
NCT03065816Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Z0063 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Sanofi. Primary endpoint: Area Under Curve of Investigational Medicinal Product Percentage Retention in the Whole Stomach at 4 hours. Started Feb 2017; status: completed.
02
Drugs
Z0063
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03065816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065816.